Most Recent Articles by Carlos Harrison
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.
Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.
Using Autologous Tumor-Infiltrating Lymphocytes to Mediate Tumor Regression: Promising Outcomes in Experimental ResearchJul 30, 2018
Experimental research may provide a blue print for the treatment of many types of cancer.
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs.
More Articles by Carlos Harrison
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJun 19,2018
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJun 18,2018
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models